Vertex Buys ViaCyte and its Stem Cell-Based Diabetes Treatment for $320M
Previously Published on Fiercebiotech.com – Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million. The all-cash deal announced Monday throws a net around ViaCyte’s stem cell-based treatment for type 1 diabetes, which has…